Myocardial Alternative RNA Splicing and Gene Expression Profiling in Early Stage Hypoplastic Left Heart Syndrome by Ricci, Marco et al.
Myocardial Alternative RNA Splicing and Gene
Expression Profiling in Early Stage Hypoplastic Left Heart
Syndrome
Marco Ricci
1*, Yanji Xu
2, Harriet L. Hammond
3, David A. Willoughby
4, Lubov Nathanson
5, Maria M.
Rodriguez
6, Matteo Vatta
7,8, Steven E. Lipshultz
9, Joy Lincoln
3
1Division of Cardiothoracic Surgery, University of Miami Miller School of Medicine and Holtz Children’s Hospital/Jackson Memorial Hospital, Miami, Florida, United States of
America,2ShaunandLillyInternational,LLC,Palm City,Florida,United States ofAmerica, 3Center forCardiovascular andPulmonary Research,NationwideChildren’sHospital,
Department of Pediatrics, The Ohio State University, Columbus, Ohio, United States of America, 4Ocean Ridge Biosciences LLC, Palm Beach Gardens, Florida, United States of
America, 5Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, United States of America, 6Department of Pathology, University of
Miami Miller School of Medicine and Holtz Children’s Hospital, Miami, Florida, United States of America, 7Division of Pediatric Cardiology, Texas Children’s Hospital/Baylor
College of Medicine, Houston, Texas, United States of America, 8Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Texas, United
States of America, 9Department of Pediatrics, University of Miami Miller School of Medicine and Holtz Children’s Hospital, Miami, Florida, United States of America
Abstract
Hypoplastic Left Heart Syndrome (HLHS) is a congenital defect characterized by underdevelopment of the left ventricle and
pathological compensation of the right ventricle. If untreated, HLHS is invariably lethal due to the extensive increase in right
ventricular workload and eventual failure. Despite the clinical significance, little is known about the molecular
pathobiological state of HLHS. Splicing of mRNA transcripts is an important regulatory mechanism of gene expression.
Tissue specific alterations of this process have been associated with several cardiac diseases, however, transcriptional
signature profiles related to HLHS are unknown. In this study, we performed genome-wide exon array analysis to determine
differentially expressed genes and alternatively spliced transcripts in the right ventricle (RV) of six neonates with HLHS,
compared to the RV and left ventricle (LV) from non-diseased control subjects. In HLHS, over 180 genes were differentially
expressed and 1800 were differentially spliced, leading to changes in a variety of biological processes involving cell
metabolism, cytoskeleton, and cell adherence. Additional hierarchical clustering analysis revealed that differential gene
expression and mRNA splicing patterns identified in HLHS are unique compared to non-diseased tissue. Our findings
suggest that gene expression and mRNA splicing are broadly dysregulated in the RV myocardium of HLHS neonates. In
addition, our analysis identified transcriptome profiles representative of molecular biomarkers of HLHS that could be used in
the future for diagnostic and prognostic stratification to improve patient outcome.
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Introduction
In Hypoplastic Left Heart Syndrome (HLHS), the right
ventricle (RV) is exposed to pressure overload, volume overload,
and hypoxia.[1,2] Despite recent medical advances, RV failure
remains the leading cause of death in children with HLHS.[3]
Recent studies have identified HLHS as a heritable phenotype
associated with certain chromosomal regions,[4,5] however, to our
knowledge, the molecular pathobiological state of HLHS has not
been examined. Identifying biomarkers of disease state and
progression is important for prognostic and therapeutic purposes
to ultimately improve patient outcome.
Alterations in mRNA expression and splicing have previously
been reported in a wide range of adult cardiac disease states,[6,7]
and affected transcripts have been considered as biomarkers of
adult cardiomyopathies and heart failure.[8], [9] Alternative
mRNA splicing is an important mechanism for generating
transcriptional diversity and regulating gene expression in specific
tissues, including the myocardium.[10] An increasing number of
human disease states have been attributed to alterations in mRNA
splicing as a result of genetic mutations and/or environmental
causes.[11] Further, the development of global exon level
interrogation techniques have provided insights into the pathobi-
ology of these disease processes at the level of cell- and tissue-
specific mRNA splicing events.[12], [13] Despite emerging studies
examining transcriptome profiles in adult cardiac disease, the
mRNA events associated with congenital heart disease (CHD) are
less well understood. Genetic studies have suggested a possible role
of mRNA alternative splicing in the pathogenesis of certain types
of CHD.[14,15] However to our knowledge, genome-wide mRNA
expression and splicing profiling has not been utilized to
investigate the myocardial pathobiology of HLHS.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29784The objective of this study was to characterize mRNA
expression and splicing patterns in the RV myocardium of HLHS
newborns by utilizing genome-wide exon-level interrogation,
hypothesizing that mRNA expression and splicing profiles are
dysregulated in the HLHS myocardium as compared to control
LV and RV myocardium. As RV failure is the strongest predictor
of long-term outcome in HLHS, our study focused on defining the
gene expression and splicing patterns in the HLHS right
ventricular myocardium to provide insights into the molecular
mechanisms associated with RV adaptation or remodeling. In
addition, as previous work by our group has shown that TGF-b-
associated gene expression profiles in the HLHS-RV share greater
molecular similarities with Control-LV than Control-RV,[16] we
included HLHS-RV versus Control-LV comparisons in our
analysis. Using this approach, our analyses revealed previously
unappreciated insights into the molecular pathobiological state of
early stage HLHS. The findings from this study provide candidate
genes for the development of therapeutic assays that could
improve prognostic stratification and clinical management of
children with HLHS.
Methods
Tissue collection
This study was approved by the Institutional Review Board at
the University of Miami (Protocol #20101106). For this study,
tissue samples were collected from three experimental groups as
follows: 1) six RV samples from neonates with HLHS (HLHS-
RV), 2) five RV samples from control neonates (control-RV), and
3) five LV samples from the same control neonates (control-LV).
As previously reported,[16] RV myocardial samples were obtained
at the time of surgery from six neonates with HLHS undergoing
Stage 1 Norwood reconstruction (See Results and Table 1).
Myocardial sampling was carried out after institution of
cardiopulmonary bypass and prior to induction of cardioplegic
arrest. The diagnosis of HLHS was defined as previously reported
by others.[3] Myocardial tissue from non-diseased controls was
obtained at autopsy from the left ventricle (LV) and right ventricle
(RV) of five newborn with normal cardiac anatomy, as previously
described by our group[16] and others.[17]
-18 Autopsy specimens
were collected by the same operator and absence of heart valve
pathology was confirmed during post-mortem examination.
Consistent with HLHS tissue harvesting, full-thickness RV tissue
was obtained from the same area of the RV free wall in controls,
whereas LV tissue was obtained from the mid-portion of the free
wall. In each experimental group, approximately 50 mg of
ventricular tissue were removed, snap frozen in liquid nitrogen,
and stored at 280uC until RNA extraction.
RNA preparation and processing
RNA was extracted using TRIzol reagent (Invitrogen) or
Qiagen RNeasy Mini Kit according to the manufacturer’s
instructions. In all samples, RNA integrity and purity were
determined with the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Inc., Santa Clara, CA). For microarray analysis, RNA
samples were amplified and labeled using NuGEN Ovation Pico
WTA system, WT-Ovation Exon module and Encore Biotin
Module (NuGEN, San Carlos, CA). Briefly 20 to 50ng of total
RNA were subjected to the synthesis of first-strand cDNA using
a unique DNA/RNA chimeric primer mix and reverse
transcriptase. DNA-RNA heteroduplex double-strand cDNA
was generated and subjected to SPIA amplification, using an
SPIA DNA/RNA chimeric primer, DNA polymerase and
RNase H in a homogeneous isothermal assay. The resulting
cDNA was used to generate sense transcript cDNA suitable for
fragmentation and labeling as target for Affymetrix Human
Exon 1.0 ST arrays.
Hybridization of HLHS exon arrays
Microarrays (Affymetrix Human Exon 1.0 ST Arrays)[18] were
hybridized for 17 hours at 45
oC in the Affymetrix Hybridization
Oven 645 according to the manufacturer’s instructions. After
hybridization, microarrays were washed, stained using the
Affymetrix Fluidics Station 450, and scanned with the Affymetrix
Scanner 3000 7G.
Analysis of microarray data
Images were analyzed with the Affymetrix Command Console
Software. The resulting CEL files were loaded into Exon Array
Analyzer (http://eaa.mpi-bn.mpg.de/) and R respectively for
quality control, and then processed by Affymetrix power tools
(APT) for background correction, normalization, and summariza-
tions with the Robust Multiple Average (RMA) algorithm to
generate exon- and gene-level intensity estimates. The analysis was
restricted to 287,329 exon-level and 22,011 gene-level core probe
sets by selecting the core.ps and core.mps file options during exon-
and gene-level processing with APT. The number of exon-level
probe sets for consideration was further reduced by removing
known cross-hybridizing exon-level probe-sets, per annotation file
‘‘HuEx-1_0-st-v2.na31.hg19.probeset.csv’’.
Table 1. Preoperative clinical and echocardiographic
characteristics of six newborns with Hypoplastic Left Heart
Syndrome.
Age, mean (range), days 5( 2t o7 )
Gestational Age, mean (range), weeks 38 (36–40)
Sex, male/female 3/3
Echocardiographic Data: n=6 neonates
Ascending Aortic Size, mean (range), mm 2.2 (1.7–3.9)
Aortic Atresia (AA) vs. Stenosis (AS)
AA 5
AS 1
Mitral Atresia (MA) vs. Stenosis (MS)
MA 5
MS 1
Tricuspid Regurgitation
None 1
Trivial 2
Mild 3
RV Function* 4
Normal 2
Mildly reduced
Atrial Septum
Non-obstructed 5
Mild obstruction 1
Ductus Arteriosus
Non-obstructed 6
Obstructed 0
*RV function was defined qualitatively
doi:10.1371/journal.pone.0029784.t001
mRNA Profiling in Hypoplastic Left Heart Syndrome
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29784Setting analysis thresholds. A custom ‘R’ script was then
used to eliminate data for non-expressing genes and exons from
the data set prior to hypothesis testing. In the first filtration step,
exon-level probe sets were marked as detected when the
Affymetrix-provided detection above background (DABG) p
value was ,0.05 in ,50% of the samples of at least one of the
three treatment groups. In the second filtration step, a transcript
cluster was marked as detected if .50% of exon-level probe sets
comprising the cluster were detected per filtration step 1.[19] All
exon-level probe sets marked as undetected in step 1 and all exon-
level probe sets making up undetected transcript clusters per step 2
were dropped to obtain a table of 166,628 detectable exon-level
probe sets. The gene-level data table from the RMA output was
then filtered to retain 13,628 transcript clusters mapping to one or
more of the detectable exon-level probe sets. Some transcript
clusters represented in the exon-level data were not represented in
the gene-level RMA output, reducing the final list of detectable
exon-level probe sets to 166,404.
The splicing index for each exon was calculated as: log2 (exon-
level probe set intensity/gene-level probe set intensity). BioCon-
ductor LIMMA package was used for differential analysis. One-
way ANOVA of splicing indexes and gene-level probe intensities
was performed to identify exon-level and gene-level probe sets (i.e.
transcript clusters) showing significant changes in intensity among
the three treatment groups. T tests were additionally used for
comparisons amongst two groups: HLHS-RV vs. Control-RV and
HLHS-RV vs. Control-LV. The false discovery rate (FDR) for
each P value was calculated by the method of Benjamini and
Hochberg.[20]
Venn Diagrams. Genes corresponding to differentially
expressed transcript clusters or exon probe sets with an altered
splice index were selected for representation in Venn diagrams
and further pathway analysis, providing threshold criteria were
met (FDR of ,0.05 in the three-group one way ANOVA, an FDR
,0.05 in the t-test for the specific two group comparison, and an
intensity or splice-index (exon probes) difference of .1.5-fold).
WebGestalt Software (Vanderbilt University)[21] was used to
identify KEGG pathways showing a statistically significant over-
representation of genes with altered total mRNA or exon levels in
the HLHS-RV samples compared to control groups. The 13,628
transcript clusters (genes) that showed detectable signal on the
array were used as the reference set for calculating statistical
significance in the pathway analysis. Venn Diagram Plotter was
used to draw Venn diagrams to compare genes either with
significant alternative splicing or significant overall expression
changes within different groups.
Clustering analysis. Criteria for selection of differentially
expressed transcript clusters or exon probe sets with an altered
splice index for display in hierarchical clustering was the same as
for the pathway analysis, other than a 2-fold change threshold in
gene-level probe set intensity or a 5-fold change in splicing-index
for exon-level probe sets were applied. Data for the detectable
probes were clustered using Cluster 3.0 software.[22] The log2-
transformed data were pre-processed by median centering of the
data for each probe set, and then hierarchically clustered using
centered correlation as the similarity metric and average linkage as
clustering method.
Principal component analysis. Principal component
analysis was conducted using Partek to visualize the overall
pattern of gene expression. All data is MIAME-compliant
(Minimum Information About a Microarray Experiment) and all
CEL files for this microarray study are available through The
Gene Expression Omnibus at: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=hfapraoacwqgwhg&acc=GSE23959.
Quantitative real-time PCR analysis. To validate
differential fold changes in gene expression between the
comparison groups from the microarray analysis, cDNA was
generated from 400 ng tRNA from human samples using the High
Capacity Reverse Transcriptase kit (Applied Biosystems). Then,
10 mL cDNA were subjected to quantitative real-time PCR using a
custom-designed Taqman Low Density Array (Applied
Biosystems) containing two endogenous controls (18s, GAPDH)
and 94 random genes that significantly changed in the microarray
analysis as described.
21 Cycle counts for each target gene were
normalized to 18s expression, and significant differences in gene
expression were reported as a fold change compared to each
experimental group.
21
Results
Myocardial gene expression and mRNA splicing are
altered in HLHS
To determine global transcriptome changes in early stage HLHS
pathogenesis, gene expression and exon array profiling (Affymetrix
Human Exon 1.0 ST Array) was performed using total RNA
isolated from the RV myocardium of neonates with HLHS (n=6)
(HLHS-RV), and compared to RNA collected from control-RV
(n=5), and control-LV (n=5) samples. For each RNA sample
collected, the analysis was performed using the Agilent Bio-analyzer
2100 to confirm consistently high levels of RNA integrity and purity
across the sample groups. The clinical and echocardiographic data
of the six HLHS neonates included in this study are shown in
Table 1.To facilitatethe interpretationofdata,neonateswith extra-
cardiac anomalies or known chromosomal defects were excluded
from the HLHS group. All 6 HLHS subjects were in a relatively
compensated hemodynamic state, had normal acid-base balance,
and received Prostaglandin E1 infusions before undergoing a Stage
1 Norwood procedure. The mean gestational age of HLHS
neonates was 38 weeks (range 36–40) and the mean postnatal age
was 5 days. For controls, the five subjects expired from various non-
cardiac disease processes including intra-ventricular hemorrhage,
meconium aspiration, and necrotizing enterocolitis. The mean
gestational age of control subjects was 33 weeks (range 26 to 39
weeks), and the mean postnatal age was 18 days.
In this study, RNA was hybridized to Affymetrix arrays
containing approximately 40 probes per gene and 4 probes per
exon, therefore allowing two complementary levels of analysis in
the same samples at the levels of gene expression and alternative
splicing, respectively. One-way ANOVA analysis was performed
to compare ‘core’ gene (17,800 transcript clusters: Refseq and full
length GenBank mRNAs) expression and alternative splicing
profiles in HLHS-RV tissue vs. Control-LV, and Control-RV
samples. Significant changes were considered with fold changes in
gene expression and splicing index .1.5 and a false discovery rate
(FDR) of ,0.05. Using these parameters to compare HLHS-RV
to control samples, a total of 183 genes were differentially
expressed: 153 genes in HLHS-RV vs. Control-LV, 96 genes
when compared to Control-RV, with 66 genes overlapping
between the two comparison groups (Figure 1A). Tables 2, 3, 4,
5 show the top ten most differentially expressed genes and
alternatively spliced transcripts in the HLHS-RV when compared
to each control group (Control-RV and Control-LV). Using exon
array analysis, we identified 1478 genes affected by alternative
splicing in HLHS-RV samples compared to control groups. Of the
1380 spliced genes in HLHS-RV vs. Control-LV, only 44 (3%)
showed significant changes in gene expression. The number of
alternatively spliced transcripts was much lower in HLHS-RV
when compared to Control-RV (525 genes), although the
mRNA Profiling in Hypoplastic Left Heart Syndrome
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expressed was similar (23 transcripts, 4%). Worthy of mention, 13
of these transcripts were common to both HLHS-RV vs. Control-
LV and HLHS-RV vs. Control-RV comparative analyses. Table
S1 lists all common and unique differentially expressed genes and
alternatively spliced transcripts within each analysis group as
indicated in Figure 1.
To confirm observations from the microarray data, a total of 94
randomly selected genes that passed the threshold criteria were
validated by quantitative real-time PCR in n=4 samples from
each subject group (HLHS-RV, Control-LV, and Control-RV).
Of the 94 genes, more than 86% showed consistent differential
changes in gene expression in HLHS-RV samples when compared
to the respective control groups. Examples of 6 validated genes
(GTF2I, LANCL2, PLOD2, SOS2, USP2 and ZFP3) are shown in
Figure 2. Collectively, this analysis validates the significance of the
microarray data and confirms the differential gene expression
observed in HLHS-RV vs. controls groups.
Clustering analysis distinguishes HLHS-RV samples from
controls
To visually represent commonality or variance in the pattern of
differentially expressed genes among the three sample groups, we
Figure 1. Venn diagrams showing the number of differentially expressed genes (A) and alternatively spliced transcripts (B)
common and unique in HLHS vs. Control-LV (red) and HLHS vs. Control-RV (green) sample groups. (C, D) Venn diagrams to indicate the
number of transcripts that were differentially expressed (red) and/or alternatively spliced (green) in HLHS-RV vs. Control-LV (C) and HLHS vs. Control-
RV (D) sample groups. Fold change in gene expression and splicing index .1.5-, FDR, False Discovery Rate ,0.05.
doi:10.1371/journal.pone.0029784.g001
Table 2. Top ten most differentially expressed genes and alternatively spliced transcripts in the HLHS-RV group: HLHS-RV vs.
Control-LV (Differential Gene Expression).
Gene Symbol
HLHS-RV vs. Control-
LV Fold Change
HLHS-RV vs.
Control-LV p-value
HLHS-RV vs.
Control-LV FDR
HLHS-RV vs. Control-
RV Fold Change
HLHS-RV vs.
Control-RV p-value
HLHS-RV vs.
Control-RV FDR
FAM129A 2.1 3.3E-07 2.3E-03 2.0 7.2E-07 2.2E-03
LANCL2 2.1 1.9E-07 2.3E-03 1.8 2.6E-06 3.0E-03
RGN 2.3 5.9E-07 2.7E-03 2.5 1.5E-07 1.5E-03
RAB3IP 2.2 1.7E-04 2.4E-02 3.2 2.1E-06 2.7E-03
MRPL46 2.5 7.7E-06 1.0E-02 2.3 2.4E-05 1.4E-02
C21orf62 2.9 9.7E-06 1.0E-02 2.8 1.3E-05 9.4E-03
IFI44 2.7 4.8E-06 1.0E-02 2.1 1.1E-04 2.9E-02
BRP44L 2.4 8.8E-06 1.0E-02 2.2 3.1E-05 1.4E-02
DCTN3 2.5 5.6E-06 1.0E-02 1.9 4.3E-04 4.6E-02
HBB 0.3 2.5E-05 1.6E-02 0.3 2.6E-05 1.4E-02
doi:10.1371/journal.pone.0029784.t002
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plot (Figure 3). This analysis illustrates similarities in transcriptome
profiles within the six HLHS-RV samples (green), and a clear
separation of profiles between HLHS-RV and the five Control-
RV (blue) samples and Control-LV (red) samples (Figure 3).
Importantly, the expression variance between HLHS-RV and
control samples was maintained irrespective of postnatal age and
gestational age, as transcriptional profiles between HLHS-RV and
control samples never overlapped, even when samples were age-
matched (Figure 3). This pattern of variance suggests that the
differences in age between HLHS and control neonates unlikely
contributed to the observed transcriptional variance between
HLHS and controls. In addition, the PCA analysis revealed a
modest transcriptional difference between Control-RV and
Control-LV samples. However, within each control group there
was substantial variability (Figure 3), likely reflecting the greater
biodiversity and clinical heterogeneity of control subjects as
compared to the more homogeneous HLHS group.
To further examine whether HLHS-RV gene expression and
alternative splicing profiles segregated from control samples,
hierarchical clustering analysis was performed. Figure 4 illustrates
clustering analysis of differentially expressed genes (Figure 4A) and
alternatively spliced transcripts (Figure 4B) in HLHS-RV vs.
indicated controls. In both clustering analyses, the 6 HLHS-RV
samples clustered separately from all control samples. Interesting-
ly, hierarchical clustering of the 5 Control-LV and Control-RV
samples was indistinguishable, suggesting indifferent gene expres-
sion and splicing profiles.
Several biological processes are dysregulated in the
HLHS myocardium
To determine the biological processes altered in the early stage
HLHS-RV pathogenesis, KEGG pathway analysis was performed.
Figure 5 shows the significantly affected KEGG pathways as a
result of differential changes in gene expression (Figure 5A) and
alternatively spliced transcripts (Figure 5B) in HLHS-RV samples
vs. Control-LV (light grey bars) and vs. Control-RV (dark grey
bars). At the gene expression level, ‘oxidative phosphorylation’ was
most significantly altered (p=1.75E-05) in HLHS-RV compared
to Control-LV samples. This process, along with other cell
metabolism activities including ‘propanoate metabolism’ were also
significantly affected (p=8.04E-05) in HLHS-RV when compared
to Control-RV samples. At the level of mRNA splicing,
‘spliceosome’ and ‘arrhythmogenic right ventricle cardiomyopa-
Table 3. Top ten most differentially expressed genes and alternatively spliced transcripts in the HLHS-RV group: HLHS-RV vs.
Control-RV (Differential Gene Expression).
Gene Symbol
HLHS-RV vs. Control-
LV Fold Change
HLHS-RV vs.
Control-LV p-value
HLHS-RV vs.
Control-LV FDR
HLHS-RV vs. Control-
RV Fold Change
HLHS-RV vs.
Control-RV p-value
HLHS-RV vs.
Control-RV FDR
FAM129A 2.1 3.3E-07 2.3E-03 2.0 7.2E-07 2.2E-03
RGN 2.3 5.9E-07 2.7E-03 2.5 1.5E-07 1.5E-03
USP2 1.9 6.4E-06 1.0E-02 2.3 2.2E-07 1.5E-03
AIFM1 1.8 8.8E-06 1.0E-02 2.0 1.1E-06 2.2E-03
PSD3 1.9 6.4E-05 1.9E-02 2.5 6.7E-07 2.2E-03
COQ10A 1.9 1.3E-04 2.3E-02 2.6 1.8E-06 2.7E-03
COL6A3 0.6 1.3E-03 5.2E-02 0.4 1.9E-06 2.7E-03
RAB3IP 2.2 1.7E-04 2.4E-02 3.2 2.1E-06 2.7E-03
MRPL46 2.5 7.7E-06 1.0E-02 2.3 2.4E-05 1.4E-02
C21orf62 2.9 9.7E-06 1.0E-02 2.8 1.3E-05 9.4E-03
doi:10.1371/journal.pone.0029784.t003
Table 4. Top ten most differentially expressed genes and alternatively spliced transcripts in the HLHS-RV group: HLHS-RV vs.
Control-LV (Alternatively Spliced Transcripts).
Gene Symbol
HLHS-RV vs. Control-
LV Fold Change
HLHS-RV vs.
Control-LV p-value
HLHS-RV vs.
Control-LV FDR
HLHS-RV vs. Control-
RV Fold Change
HLHS-RV vs.
Control-RV p-value
HLHS-RV vs.
Control-RV FDR
INADL 5.38 1.5E-02 4.91 1.2E-04 4.1E-02 1.5E-02
SPTA1 0.16 6.4E-03 0.13 2.0E-06 6.5E-03 6.4E-03
ENAH 0.16 2.2E-08 4.0E-04 0.21 2.1E-07 2.4E-03
RYR2 6.02 1.6E-05 7.8E-03 3.47 6.9E-04 8.0E-02
ITGB1BP1 5.53 6.4E-07 1.9E-03 2.95 1.4E-04 4.3E-02
IFT172 0.18 1.2E-04 1.8E-02 0.43 2.5E-02 3.0E-01
C2orf55 5.24 5.6E-04 3.6E-02 5.68 3.6E-04 6.2E-02
GYPB/GYPA 0.16 7.3E-07 1.9E-03 0.17 1.0E-06 4.4E-03
CPNE5 0.16 4.0E-05 1.1E-02 0.44 2.4E-02 3.0E-01
C6orf186/DDO 6.49 2.8E-06 3.8E-03 2.91 1.1E-03 9.4E-02
doi:10.1371/journal.pone.0029784.t004
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Control-RV (Alternatively Spliced Transcripts).
Gene Symbol
HLHS-RV vs. Control-
LV Fold Change
HLHS-RV vs.
Control-LV p-value
HLHS-RV vs.
Control-LV FDR
HLHS-RV vs. Control-
RV Fold Change
HLHS-RV vs.
Control-RV p-value
HLHS-RV vs.
Control-RV FDR
SPTA1 0.05 2.0E-09 8.4E-05 0.07 9.9E-09 4.2E-04
MXD1 0.21 4.2E-05 1.2E-02 0.17 6.8E-06 1.1E-02
GYPB/GYPA 0.16 7.3E-07 1.9E-03 0.17 1.0E-06 4.4E-03
GRM1 4.84 7.4E-05 1.5E-02 5.04 5.7E-05 2.9E-02
ANK1 3.60 6.3E-04 3.8E-02 6.18 1.7E-05 1.6E-02
CACNB2 0.17 2.1E-05 8.8E-03 0.18 3.2E-05 2.2E-02
CCNJ 0.17 5.5E-10 5.8E-05 0.19 1.1E-09 1.8E-04
PPFIA2 4.00 1.9E-04 2.2E-02 5.43 2.2E-05 1.9E-02
PMP22 2.40 2.0E-03 6.6E-02 5.89 1.1E-06 4.6E-03
PLD6 2.16 4.4E-02 2.8E-01 5.84 1.1E-04 4.0E-02
doi:10.1371/journal.pone.0029784.t005
Figure 2. Validation of the microarray data by real-time qPCR on randomly selected genes. Dark grey bars indicate microarray findings
and light grey bars indicate qPCR results. Error bars show SEMs. * p,0.05 in HLHS-RV compared to indicated control groups.
doi:10.1371/journal.pone.0029784.g002
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compared to Control-LV and Control-RV samples, respectively.
The differentially expressed genes and alternatively spliced
transcripts associated with these altered KEGG pathways are
included in Table 6. These findings suggest a broad dysregulation
in mRNA expression and splicing patterns in the HLHS
myocardium involving a variety of biological processes.
Exon abundance of individual genes is altered in HLHS
To determine alterations in the abundance of individual exons
of alternatively spliced genes in HLHS-RV, expression profiling
was performed. Figure 6 shows the splicing index of pre-designed
probe sets that hybridized at nucleotide positions consistent with
individual exons of the top three transcripts affected my mRNA
splicing (but not gene expression) in HLHS-RV samples compared
to controls. As indicated by the arrows, HLHS-RV samples show
distinct exon-specific expression profiles compared to control
samples and provide insights into the post-transcriptional events
active in early stage HLHS.
Discussion
Recent studies have partly unveiled the chromosomal loci
associated with hereditary HLHS,[4,5] however the molecular
pathobiology of this disease remains poorly understood. Recent
studies have demonstrated significant changes in mRNA expres-
sion and splicing profiles in a variety of adult cardiac pathophys-
iologic states, although transcriptome alterations in CHD have not
been reported.[12] To address this, we performed a genome-wide
exon array and found significant changes in gene expression and
alternative splicing events in the RV of a representative cohort of
infants with HLHS compared to non-diseased controls. These
transcriptome alterations were associated with changes in a variety
of biological processes involving cell metabolism, the cytoskeleton,
cell adherence and mRNA processing. Further, hierarchical
clustering based upon gene expression and alternative splicing
analysis data revealed unique molecular profiles segregating
HLHS-RV samples from LV and RV control samples. Collec-
tively, our findings provide new insights into the transcriptional
events active in the RV myocardium of early stage HLHS. In
addition, they provide the basis for the identification of novel
transcriptome-based markers of disease state that may be useful for
prognostic stratification and treatment purposes.
Signature profiles of gene expression have been used as tools for
diagnostic and prognostic purposes in human cardiomyopa-
thies.[23] In this study of congenital heart disease, a total of 183
core genes passed threshold criteria and were considered
differentially expressed in HLHS-RV samples compared to
controls. Among these, 66 genes overlapped between the two
comparison groups (HLHS-RV vs. Control-LV and HLHS-RV
Figure 3. Principal component plot of normalized gene expression values from microarray analysis of six HLHS (green), five
Control-LV (red), and five Control-RV (blue) samples. Gestational age (in weeks) and postnatal age (in days) of each subject is indicated in
parentheses. HLHS-RV samples segregated apart from all Control-RV and Control-LV samples, irrespective of post-natal age and gestational age. Post-
natal and gestational age did not appear to result in any particular trend either within the HLHS or the control groups.
doi:10.1371/journal.pone.0029784.g003
mRNA Profiling in Hypoplastic Left Heart Syndrome
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29784vs. Control-RV). However, of the differentially expressed tran-
scripts that were not common, the genetic profile of HLHS-RV
was most similar to Control-RV. This observation is in contrast to
our previous study showing that activity of TGF-b signaling
pathways in HLHS-RV was most similar to Control-LV.[16]
Despite the unique genetic profiles in HLHS-RV vs. Control-LV
and Control-RV, differentially expressed genes associated with
‘oxidative phosphorylation’ were similarly affected in HLHS-RV
when compared to each of the control groups (Table 6). Based
upon the pathophysiological exposure of the RV to pressure
overload, volume overload and hypoxia in HLHS, the overrep-
resentation of oxidative phosphorylation and other metabolic
genes (Figure 5, Table 6) in the HLHS-RV myocardium suggest a
shift from normal fatty acid metabolism to glucose metabolism
found in myocytes undergoing hypertrophy. [24,25] In addition, it
is likely that the differential gene expression profile observed in
HLHS-RV samples is representative of early post-natal adaptive
RV remodeling in response to compensatory changes in
myocardial hypertrophic growth. It is therefore surprising that
other genes associated with myocardial hypertrophy were not
differentially expressed including extracellular matrix genes and
regulatory transcription factors. We suspect that this may be due
to the collection of RNA from newborns with HLHS and not older
patients in whom the RV remains exposed to pressure/volume
overload and hypoxia for a longer period of time. However, more
long-term studies are required to confirm this hypothesis.
In addition to altered whole-gene expression patterns, altered
splicing patterns resulting in differential exon abundance in HLHS
tissue are also consistent with other studies of adult cardiac disease
states.[12]
, [26]
, [27] Similar to differential gene expression, cell
metabolism processes were also significantly altered by mRNA
splicing. However, KEGG pathway analysis revealed that splicing
events also led to significant changes in transcripts associated with
‘spliceosome’ and ‘adherens junctions’ categories in HLHS-RV
compared to Control-LV, and ‘arrhythmogenic right ventricle
cardiomyopathy’ when compared to Control-RV. The individual
transcripts affected within these broad KEGG categories included
genes associated with mRNA processing (Prp 2, 16–18, 53),
consistent with the overrepresentation of the ‘spliceosome’ and
consistent with splicing events. In addition, genes involved with
cell-cell communication (CTNNB1, DSG2, ITGB3, CDH2), cyto-
skeleton (DMD, SGCG), and calcium movement (CACNA1C,
CACNB2) were largely underexpressed in HLHS-RV. These latter
changes are consistent with compensatory remodeling in the RV
of HLHS patients to support pathophysiological changes in
hemodynamic load as a result of an underdeveloped LV. Although
Figure 4. Hierarchical clustering and heat map analysis of differential gene expression (A) and alternatively spliced (B) profiles in
HLHS-RV vs. Control-RV and Control-LV samples. Clustering was performed on log2-transformed and normalized gene-level probe set
intensities and splicing indexes for transcript clusters or exon-level probe sets, respectively, that met specific significance and fold-change criteria (see
Methods). Except for the right image of panel A, all of the probe sets meeting the specific criteria are displayed. Note significant clustering of HLHS
samples compared to controls that show indistinguishable identity. Key: one unit=a difference of one log2 unit from the gene (A) or splicing index
(B) mean for all the samples.
doi:10.1371/journal.pone.0029784.g004
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expression and mRNA splicing are causative of HLHS or the
result of adaptive or maladaptive myocardial changes in the RV
myocardium of HLHS subjects. Nonetheless, this analysis provides
insights into the biological processes that are altered in the HLHS-
RV as a result of changes in transcriptome profiles.
In this study we have identified a number of differentially
expressed and differentially spliced transcripts that have the
Figure 5. KEGG pathway analysis to show the relative significance of affected biological processes in HLHS-RV samples versus
controls as a result of differential gene expression and alternative splicing events. Numbers indicate the number of differentially
expressed or alternatively spliced transcripts that within each indicated KEGG category.
doi:10.1371/journal.pone.0029784.g005
Table 6. Most significantly affected KEGG pathways by differentially expressed genes and alternatively spliced transcripts in the
HLHS-RV group.
KEGG Pathway
Differentially
Expressed Genes
Fold Change
(HLHS-RV vs.
Control-LV) p-value FDR
Fold Change
(HLHS-RV vs.
Control-RV) p-value FDR
Oxidative Phosphorylation: 1.75E-05
NDUFV1 1.7 4.4E-04 3.4E-02 1.7 3.8E-04 4.3E-02
NDUFS1///LOC100329109 1.9 1.4E-04 2.4E-02 1.9 1.4E-04 3.2E-02
NDUFB6///DFFB 2.8 1.9E-04 2.4E-02 2.2 1.8E-03 8.0E-02
UQCRQ 3.5 1.8E-04 2.4E-02 2.0 1.7E-02 2.0E-01
UQCR10 2.1 5.2E-04 3.6E-02 2.0 1.1E-03 6.8E-02
SEC31B 1.8 3.2E-05 1.7E-02 1.9 1.1E-05 8.1E-03
NDUFAB1 2.0 1.1E-04 2.1E-02 1.8 9.6E-04 6.5E-02
COX4I1 1.6 3.3E-04 3.0E-02 1.5 9.2E-04 6.4E-02
ATP5A1 1.6 9.6E-05 2.0E-02 1.7 2.7E-05 1.4E-02
SNORD59A/// 1.6 7.0E-05 1.9E-02 1.6 8.8E-05 2.8E-02
NDUFA8 2.4 8.2E-05 2.0E-02 2.1 3.3E-04 4.2E-02
Propanoate Metabolism: 8.04E-05
ACAT1///ACAT1 1.9 9.2E-04 4.5E-02 2.1 4.1E-04 4.5E-02
PCCB//PCCB 1.9 1.8E-04 2.4E-02 1.8 3.4E-04 4.2E-02
ALDH1B1 2.1 5.9E-05 1.9E-02 2.0 2.0E-04 3.6E-02
ECHS1 1.5 4.9E-04 3.5E-02 1.5 2.1E-04 3.6E-02
doi:10.1371/journal.pone.0029784.t006
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include differential expression and splicing of calcium transporter
(SLC8A1, CACNB2, RYR1) and energy metabolism (COX4I1,
ACAT1, ATP5A1) genes, as well as structural proteins (STPB,
DCTN5, XIRP2), detectable in myocardial samples obtained from
HLHS patients during surgical intervention. In addition to tissue-
specific biomarkers, levels of secreted factors (IFI44, VEGFA) and
cell surface markers (PROM1) have previously shown to be
measurable in serum samples and serve as biomarkers for other
pathological states.[28] Our findings also revealed that, in HLHS,
less than 5% of alternatively spliced transcripts are also
differentially expressed. In addition, we have also observed that
splicing events result in variable levels of individual exon
abundance, suggesting that gene dosage may have important
implications in understanding the mechanisms of HLHS and RV
failure. Therefore, in the development of a prognostic and
therapeutic HLHS biomarker assay, it is important to use exon
interrogation and include splicing profiling to target specific
chromosomal exon locations as an adjunct to gene expression
analysis. As HLHS remains associated with a considerable risk of
RV failure, this study holds promise as it establishes the basis for
using mRNA expression-based and splicing-based profiling in
myocardial tissue or even in serum samples for prognostic
purposes and to guide therapeutic interventions.
We acknowledge that this study presents several limitations.
While somewhat uncontrollable, it is recognized that compared to
HLHS subjects, control tissue was obtained from a heterogeneous
group of newborns aged ,37 weeks of gestation who died from
non-cardiac disease states. Although our PCA selective analysis
(Fig. 3) suggests that pre-natal age was unlikely a major contributor
to differential expression, it is possible that this factor introduced a
bias in our study. Similarly, the unavoidable deterioration or stress
in the control subjects during the period leading to their demise
might have played a role. Unfortunately, sudden neonatal death
due to non-cardiac causes is a very rare event, and therefore ideal
control subjects are usually not available. Also, while our analysis
provides a descriptive cross-sectional assessment of genomic
profiling at a specific maturational age, it does not identify which
pathways are active during fetal life or in subsequent develop-
mental stages. Further work is required to determine transcrip-
tome profiles in a larger cohort of HLHS subjects at different
stages of disease state. Also, it is exceedingly difficult to obtain
myocardial tissue from age-matched control living subjects and it
is recognized that this might have introduced a bias, although
RNA quality from post-mortem samples was consistent with that
from HLHS subjects. Finally, our approach is unable to
distinguish between mRNA splicing events causative of HLHS
phenotypes and those that are secondary to pathophysiology-
induced alterations.
In conclusion, using genome-wide exon interrogation we have
identified new mRNA expression and splicing signature profiles
associated with early stage HLHS pathobiology. Our findings
suggest that mRNA expression and splicing are broadly dysreg-
ulated in the RV myocardium of HLHS neonates. This study
provides novel clues into the molecular events and biological
processes associated with neonatal HLHS pathobiology. In
addition, this dataset establishes the basis for future investigations
to identify transcriptome-based biomarkers of disease severity and
progression that could be useful for diagnostic and prognostic
stratification to improve patient outcome.
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